Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Colombo

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Exploration of Targeted Anti-Tumor Therapy|November 10, 2025
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunitiesSara Parola, Ilaria Colombo
Exploration of Targeted Anti-Tumor Therapy|July 5, 2024
Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunitiesElena Trevisi, Cristiana Sessa, Ilaria Colombo
Cancer Drug Resistance (Alhambra, Calif.)|July 25, 2024
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancerBertha Alejandra Martinez-Cannon, Ilaria Colombo
Drug Design, Development and Therapy|April 3, 2018
Rucaparib: a novel PARP inhibitor for <i>BRCA</i> advanced ovarian cancerIlaria Colombo, Stephanie Lheureux, Amit Manulal Oza
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatmentSofia Genta, Federica Martorana, Anastasios Stathis, et al.
Cancer Treatment Reviews|September 6, 2020
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidencesLaura Carrassa, Ilaria Colombo, Giovanna Damia, et al.
Frontiers in Immunology|December 8, 2025
Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancerEmily Frances Brown, Ilaria Colombo, Ainhoa Madariaga, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?Marta Nerone, Maria Del Grande, Cristiana Sessa, et al.
Cancers|June 28, 2023
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker DiscoveryIlaria Colombo, Katherine Karakasis, Sneha Suku, et al.
Cancers|February 25, 2022
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting AgentsFederica Martorana, Leandro Apolinario Da Silva, Cristiana Sessa, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Exploration of Targeted Anti-Tumor Therapy|November 10, 2025
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunitiesSara Parola, Ilaria Colombo
Exploration of Targeted Anti-Tumor Therapy|July 5, 2024
Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunitiesElena Trevisi, Cristiana Sessa, Ilaria Colombo
Cancer Drug Resistance (Alhambra, Calif.)|July 25, 2024
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancerBertha Alejandra Martinez-Cannon, Ilaria Colombo
Drug Design, Development and Therapy|April 3, 2018
Rucaparib: a novel PARP inhibitor for <i>BRCA</i> advanced ovarian cancerIlaria Colombo, Stephanie Lheureux, Amit Manulal Oza
Critical Reviews in Oncology/Hematology|November 20, 2021
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatmentSofia Genta, Federica Martorana, Anastasios Stathis, et al.
Cancer Treatment Reviews|September 6, 2020
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidencesLaura Carrassa, Ilaria Colombo, Giovanna Damia, et al.
Frontiers in Immunology|December 8, 2025
Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancerEmily Frances Brown, Ilaria Colombo, Ainhoa Madariaga, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?Marta Nerone, Maria Del Grande, Cristiana Sessa, et al.
Cancers|June 28, 2023
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker DiscoveryIlaria Colombo, Katherine Karakasis, Sneha Suku, et al.
Cancers|February 25, 2022
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting AgentsFederica Martorana, Leandro Apolinario Da Silva, Cristiana Sessa, et al.
Pageof 5